- 2 Years of Immunotherapy for Advanced Lung Cancer Might Be Enough: Study
- AHA News: This Fitness Instructor Had a Stroke at 36
- Smoke From Wildfires Is Especially Tough If You Have Asthma. Here’s How to Protect Yourself
- Diabetes Med Metformin Might Help Prevent Long COVID
- FDA Panel Backs RSV Vaccine for Infants, Some Toddlers
- Young Adults’ Use of Hallucinogens Like Mushrooms, PCP Doubled in a Few Years: Study
- Disability a Growing Concern for U.S. Cancer Survivors
- Long Space Flights Could Take Toll on Astronauts’ Brains
- Seizures While Driving Highlight Importance of Early Diagnosis of Epilepsy
- Nutrient Taurine Might Help Extend Life, Animal Studies Show
Tretten Approved for Genetic Clotting Disorder

Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.
People with the genetic disorder do not make enough Factor XIII, a blood component that promotes clotting. Tretten, a human recombinant produced in yeast cells, makes up for this deficiency, which could otherwise be life threatening, the FDA said Monday in a news release.
Tretten was evaluated in a clinical study of 77 people with the disorder. Administered monthly, it was effective in preventing bleeding in 90 percent of recipients. Side effects included headache, extremity pain and pain at the injection site. No study participant developed abnormal clotting, the FDA said.
The product was developed and is produced by Novo Nordisk, based in Denmark.
More information
To learn more about this disorder, visit the National Hemophilia Foundation.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.